secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009880
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics provides pipeline update: CTX310 advances to Phase 1b; zugo-cel shows durable remission in SLE
--------------------------------------------------------------------------------

- CTX310 (ANGPTL3) advanced to Phase 1b for severe hypertriglyceridemia and refractory hypercholesterolemia after positive Phase 1 data.
- CTX320 (LPA) showed up to 73% reduction in dose escalation; next-gen CTX321 with ~2-fold greater potency in preclinical testing.
- Zugo-cel (CTX112): first SLE patient in drug-free DORIS remission at month 9; second SLE patient with SLEDAI-2K 0 at month 2.
- Collaboration with Eli Lilly to evaluate zugo-cel + pirtobrutinib in aggressive B-cell lymphomas.
- Next-gen diabetes candidate CTX213 progressing towards clinic after promising CTX211 data showing C-peptide at 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526009880/0001193125-26-009880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526009880/crsp-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer